Treasury, IRS Proposes Updates to Prescription Drug Fee Rules (1)

The Treasury Department and IRS on Wednesday proposed rules related to the annual fees imposed on businesses that manufacture or import certain branded prescription drugs.

The proposed rules (RIN 1545-BR16) would make updates regarding the discounts, rebates, and other price concessions used to determine branded prescription drug sales under Medicare Part D.

The updates to the Branded Prescription Drug Fee regulations would reflect a new discount program implemented under the Biden-era Inflation Reduction Act.

The current regulations cite the Centers for Medicare & Medicaid Services’ Coverage Gap Discount Program, but the proposed rule would update them to reflect ...